RxDoctor Payments Data

Erica Benvenutti, MD

Rheumatology · Oklahoma City, OKNPI 1699088963

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 199 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,929, 9.6 times the $201 reported in 2019. That places this record below the midpoint for rheumatology clinicians in OK, where the typical reported total is $4,359.

$5,164in general payments, 2019–2025

Across 199 payments — averaging $25.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$878
  • UCB, Inc.$744
  • GSK$595
  • Amgen$403
  • AstraZeneca$364
  • Johnson & Johnson$348
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$5,13799%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,164 in reported general payments places this provider in the 50th percentile of 67 rheumatology providers in Oklahoma.

See all rheumatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$27,887
Medicare patients
97
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab29$204,688
Taltz SyringeIxekizumab11$74,852
MethotrexateMethotrexate Sodium66$1,882
Leflunomide19$1,550
Hydroxychloroquine Sulfate42$1,097
Sulfasalazine13$420
Celecoxib14$207
Prednisone23$203
Meloxicam13$55

Paid to pharmacies, not to this prescriber.

Other rheumatology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →